JIM
VNDA icon

Jupiter Investment Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Jupiter Investment Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-52,372
Closed -$835K – 480
2016
Q4 		$835K Buy
+52,372
New +$842K 0.01% 224

Other funds holding VNDA

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jupiter Investment Management's VNDA Position: Q1 2017 in Review

Jupiter Investment Management sold out of Vanda Pharmaceuticals (VNDA) in Q1 2017, closing a stake of 52,372 shares — an estimated $835K sold.

Jupiter Investment Management first reported a position in VNDA in Q4 2016 and held it in 1 quarter. The position peaked at $835K in Q4 2016. 136 funds tracked by Wall St. Rank hold VNDA as of Q1 2017.

  • Jupiter Investment Management reported no remaining Vanda Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Jupiter Investment Management sold 52,372 Vanda Pharmaceuticals shares in Q1 2017, an estimated $835K.
  • Jupiter Investment Management first reported a position in Vanda Pharmaceuticals in Q4 2016 and held it in 1 quarter.
  • Jupiter Investment Management's Vanda Pharmaceuticals position peaked at $835K in Q4 2016.
  • 136 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2017.

Based on Jupiter Investment Management's 13F filing for Q1 2017, filed 27 Apr 2017.